Crystal problem highlighted in US complete response to Neupro
This article was originally published in Scrip
UCBneeds to resolve the issue of crystal formation in its patch formulation of rotigotine (Neupro) before it can be approved in the US for advanced Parkinson's disease and primary restless legs syndrome (RLS), the FDAhas told the company in a complete response letter.
You may also be interested in...
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.